Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528535 | 0.86 | F2 (0.35) | F2MYCWDR5 | |
| SCHEMBL5386317 | 0.86 | PDE5A (0.36) | MYCWDR5POLBLMNAKCNA5 | |
| SCHEMBL1379630 | 0.85 | CYP2C9 (0.41) | F2MYCWDR5HCRTR1 | |
| SCHEMBL4396323 | 0.84 | F2 (0.35) | F2KCNT1POLBTHRBLMNA | |
| SCHEMBL4397521 | 0.84 | KCNT1 (0.36) | F2KCNT1POLBLMNAKCNA5 | |
| SCHEMBL4392377 | 0.84 | CLPP (0.36) | F2KCNT1POLBTHRBLMNA | |
| SCHEMBL4036523 | 0.83 | F2 (0.37) | F2KCNT1HCRTR1POLBTHRB | |
| SCHEMBL1378995 | 0.83 | CYP2C9 (0.42) | F2MYCWDR5HCRTR1 | |
| SCHEMBL4403363 | 0.83 | F2 (0.34) | F2KCNT1LMNAKCNA5 | |
| SCHEMBL5392599 | 0.82 | MAPT (0.36) | POLBLMNAKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749008-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7173022-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173022-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173022-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005118590-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267131-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267131-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TOP1, APOBEC3C | F2 1623/4885MYC 614/4885WDR5 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.